WHO recommends DNA testing for primary cervical cancer screening¹) and the recent trends show that screening method is shifting from the cytology test to HPV DNA test. Furthermore, the prevalence of HPV type is different across the world due to increasing vaccination and difference in regional characteristics², leading DNA testing more useful in screening HPVs. Allplex™ HPV HR Detection is a multiplex real-time PCR assay that enables simultaneous amplification and detection of target nucleic acids of 12 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) and 66, 68 as well as Internal Control (IC)

Allplex™ HPV28 Detection is a multiplex real-time PCR assay that enables simultaneous amplification and detection of target nucleic acids of 12 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59), as well as types 66 and 68, along with 14 additional HPV types (26, 53, 69, 73, 82, 6, 11, 40, 42, 43, 44, 54, 61, 70), and includes an Internal Control (IC).